Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

NCT03412383 is registered in ClinicalTrials.gov with Peking Union Medical College as lead sponsor.

NCT NCT03412383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03412383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Lead sponsor
Peking Union Medical College
Phase
Phase 2
Overall status
Unknown status
Start date
February 20, 2018
Completion date
June 25, 2019
Enrollment
14 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2 gene mutation